ANIP vs C · rev $614.4M vs P/E 16, rev $85.22B
ANI Pharmaceuticals Inc (ANIP) versus Citigroup Inc. (C) — a side-by-side from cached financials, not a winner call.
ANI Pharmaceuticals Inc (ANIP) is a drug manufacturers - specialty & generic company listed on US.
Citigroup Inc. (C) is a banks - diversified company listed on US.
Latest reported ANIP revenue for 2024-12-31 was $614.4M. Net income was -$18.5M. Revenue was up 26.2% from 2023-12-31 to 2024-12-31. ANIP currently screens at market cap $1.41B.
Latest reported C revenue for 2025-12-31 was $85.22B. Net income was $14.31B. Revenue was up 5.0% from 2024-12-31 to 2025-12-31. C currently screens at market cap $214.73B and trailing P/E 15.5.
ANIP currently screens at market cap $1.41B. C currently screens at market cap $214.73B and trailing P/E 15.5.
Not investment advice. Open the ANIP and C stock pages for the full models.
Not investment advice.